Answer
May 21, 2025 - 11:57 AM
Fidaxomicin is considered highly effective in treating Clostridioides difficile (C. diff) infections, particularly due to its ability to specifically target the bacteria with minimal disruption to the normal gut flora. Clinical studies have shown that fidaxomicin is comparable to vancomycin in initial cure rates but is superior in reducing recurrence rates of the infection. Its targeted action and reduced recurrence make it a preferred option for certain patients.
